Allogene Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Great. Good afternoon, everyone. Thanks so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have the Allogene team here with us. So we have David Chang, President, CEO and Co-Founder as well as Eric Schmidt, CFO. And maybe to start here, Eric, given the news today, maybe I just want to walk through just provide us some of your thoughts.
As you're referring to -- so Salveen, as you know, I -- we at Allogene announced my resignation today from the company, and that was with very mixed feelings as you can imagine, I've been an Allogene for 5 years, and I've had the pleasure of working with David and Ari and Christine and many others to create what I really think is a preeminent cell therapy company.
And -- in doing so, out of joy, I've been traveling back and forth, East Coast, West Coast and doing so very regularly. And of course, with that travel,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
